Robert C. Millonig, Ph.D. is a director in Sterne Kessler’s Biotechnology & Chemical Practice Group. He has significant experience developing and analyzing complex multi-patent portfolios for marketed innovator and generic pharmaceutical products. His approach to resolving legal issues revolves around reaching the solution that best meets the client’s business needs, rendering more than 5,000 opinions in the pharmaceutical space alone. Bob counsels clients in various intellectual property matters including patent validity and infringement analysis, freedom to operate, patentability investigations and FDA/ANDA practice. He is versed in the interplay between FDA regulations and patent law and has successfully co-counseled on major litigation involving patent challenges.

Specifically, Bob has been involved in developing strategy for challenging patents on fexofenidine, alendronate, raloxifine and extended release niacin to name a few. He has also provided strategic and technical counsel for top companies such as Teva Pharmaceutical Industries Ltd. and Apotex.

Bob’s extensive pharmaceutical know-how and evaluations of paragraph IV challenges enable him to evaluate and bolster innovator patent holders’ portfolios by reviewing them from a unique generic perspective.

Bob’s technical experience is focused in the areas of biochemistry, molecular and cell biology, chemistry and pharmacology. He has extensive experience prosecuting United States patent applications and providing counsel in these areas.

Bob’s dissertation research relates to the structure and polymerization of the actin filament and involved electron microscopy as well as various protein chemistry techniques. While conducting his dissertation research, Bob spent three years at the Biozentrum of the University of Basel, Switzerland.

  • J.D., The George Washington University Law School, with honors
  • Ph.D., Biochemistry, Cellular and Molecular Biology, The Johns Hopkins University
  • B.S., Biochemistry, Manhattan College, cum laude

  • District of Columbia
  • United States Patent & Trademark Office

  • American Bar Association
  • American Intellectual Property Law Association

Speaking Engagement

The Future of Obviousness: Objective Indicia of Nonobviousness and Obviousness-Type Double Patenting

New York, NY, Sheraton New York Times Square Hotel, November 9, 2021 1:30 PM - 2:30 PM EST

Related News & Insights

From Robert C. Millonig, Ph.D.

In the News

March 14, 2022

Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir.

Bloomberg Law

In the News

March 14, 2022

Fed. Circ. Affirms PTAB's Ax of Acne Drug Patent

Law360

In the News

April 1, 2020

PTAB Upholds 3 Teva Migraine Patents Challenged By Eli Lilly

Law360

In the News

May 14, 2019

Fed. Circ. Backs PTAB Ax Of J&J Prostate Cancer Drug Patent

Law360

In the News

May 14, 2019

Johnson & Johnson loses appeal to revive Zytiga patent

Reuters

Bylined Articles

May 6, 2016

Patentees: Caveat Emptor of the ‘On-Sale Bar’!

Bloomberg BNA's Patent, Trademark & Copyright Journal Multiple Authors

Bylined Articles

February 24, 2015

The Best Offense Is a Good Defense: Patent Prosecution Strategies During Personalized Medicine Drug Development

Biotechnology Law Report Marsha Rose Gillentine, Ph.D., Robert C. Millonig, Ph.D.

Bylined Articles

November 27, 2014

Divide and Conquer

World Intellectual Property Review Marsha Rose Gillentine, Ph.D., Robert C. Millonig, Ph.D.

Bylined Articles

October 29, 2014

An Alternative Attack in Inter Partes Review

Law360 Multiple Authors

Client Alert

August 27, 2014

Selection Invention Found Unpatentable For Obviousness-Type Double Patenting

Multiple Authors